when should we start using angiotensin converting enzyme inhibitors/angiotensin receptor blockers in diabetic kidney disease?
Clicks: 200
ID: 175029
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
6.0
/100
20 views
20 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus.
| Reference Key |
ivanov2017pokiwhen
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;D.D. Ivanov |
| Journal | oncology letters |
| Year | 2017 |
| DOI |
10.22141/2307-1257.6.1.2017.93781
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.